Expert Interview
Discussing the Losmapimod data for Facioscapulohumeral muscular dystrophy (FSHD) from Fulcrum Therapeutics
Ticker(s): FULCInstitution: University of Washington
- Associate Professor of Neurology at University of Washington and a researcher at the Seattle Wellstone Center.
- Manages ~15 patients with myotonic dystrophy type 1 (DM1).
- Researches focuses on inclusion body myositis, facioscapulohumeral muscular dystrophy, and ALS (funded throug the NIH), and clinical interests focus on neuromuscular disorders, such as motor neuron disease (ALS), myasthenia gravis, peripheral neuropathies and muscular dystrophies including FSHD.
How many FSHD patients do you treat?
Added By: wilson_adminWhat are your opinions of the phase 2 data?
Added By: wilson_adminWhat do you think about the phase 3 trial design?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
